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I See Dead Patents: How Bugs in the Patent
System Keep Expired Patents Alive
Dinis Cheian*
One of the most important days in the life of a patent is the day
it dies.
The moment a patent dies, the patent owner loses her monopoly
over her invention, ending the stream of income generated by that
patent. Without an enforceable patent to protect the invention, the
competitors and public can freely buy and sell copycat products that
compete with the patent owner’s. Consumers reap the rewards in
the form of more options and lower prices.
Normally, those potential competitors must wait exactly twenty
years from the date the patent application is filed with the United
States Patent and Trademark Office (“Patent Office”). But if a patent owner is lucky, her competitors may wait even longer. The Patent Office may extend the life of a patent to compensate for certain
delays in processing the application. Such an extension, known as a
Patent Term Adjustment (“PTA”), is automatically calculated by
computer software administered by the agency. But that software
makes mistakes. Because the Patent Office will not double-check the
computer’s calculations—unless the patent owner asks it to—those
mistakes are rarely discovered. These skewed incentives lead to excessive PTA that exclusively benefits the patent owners. In some industries, such as pharmaceuticals, every additional day of patent
life can result in millions of dollars of profit for the patent owner—
profits that they may not be entitled to by law—and can delay the
collapse of the price of the patented drug. It is little surprise that
fierce litigation ensues over even a single day of patent life.
*

Associate at Susman Godfrey LLP; J.D. 2021, Harvard Law School; M. Eng., B.S.
2016 Massachusetts Institute of Technology. I want to express my sincere gratitude to
Professor Mark A. Lemley, Abed R. Balbaky, Matthew E. Ladew, J. Jacob Marsh, and
Benjamin L.W. Sobel for their invaluable comments that have considerably improved this
article. The opinions expressed are those of the author and do not necessarily reflect the
views of Susman Godfrey LLP or its clients.
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This Article exposes those software mistakes and their impact
for the first time. In this Article, based on my original analysis of the
Patent Office’s data, I identify two previously undiscovered software bugs, observed in more than 27,000 patents. I demonstrate
how these bugs result in excessive PTA of, sometimes, 60–90 days.
Because there are undoubtedly more than the two identified ways in
which the software can err, I recommend that patent litigators start
routinely double-checking the PTA in order to save their clients millions in patent infringement damages. Entities seeking approval of
generic drugs should similarly take note of these bugs as they may
impact the date on which they need to file their application with the
Food & Drug Administration. I also propose regulatory changes
that would allow the Patent Office to improve the software by
crowdsourcing the identification of bugs. Finally, I recommend a
statutory change that would minimize the number of patents with
excessive PTA.
INTRODUCTION ......................................................................... 2
I. WHY PTA MATTERS AND HOW IT IS CALCULATED
............................................................................... 10
A. Calculating Patent Delay: In Theory ............... 12
B. Calculating Patent Delay: In Practice............. 16
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A. The First Bug: Forgiven Delays ...................... 21
B. The Second Bug: Backdated Events ................. 24
III. THREE SOLUTIONS ................................................. 27
A. The Private Solution......................................... 28
B. The Regulatory Solution................................... 29
C. The Statutory Solution...................................... 31
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INTRODUCTION
A patent’s expiration date is of paramount importance to the patent owner, the patent owner’s competitors, and the public. Patents
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secure a patent owner’s right to exclude others from benefiting from
an invention1 for the limited period of time of the patent’s validity
period. The validity period is also known as the “term” of the patent.2 Effectively, the patent grants its owner a quasi-monopoly on
the invention.3 If the invention is valuable, the patent generates significant revenue from, for example, direct sales of the invention or
licensing fees paid by competitors.4 Once the patent expires, the patent owner’s competitors and the public benefit from the invention
unencumbered. Competitors are free to exploit the invention by selling cheaper alternatives5 without paying licensing fees or worrying
about patent infringement suits.6 The public benefits from increased

1

Specifically, a patent grants its owner “the right to exclude others from making, using,
offering for sale, or selling the invention throughout the United States or importing the
invention into the United States, and, if the invention is a process, of the right to exclude
others from using, offering for sale or selling throughout the United States, or importing
into the United States, products made by that process, referring to the specification for the
particulars thereof.” 35 U.S.C. § 154(a)(1).
2
Generally, patents are valid for a period “beginning on the date on which the patent
issues and ending 20 years from the date on which the application for the patent was filed
in the United States . . . .” Id. § 154(a)(2). However, as I will discuss in this article, the life
of the patent can “be extended” due to delays in processing the patent application. Id. §
154(b)(1)(A).
3
See, e.g., Peter M. Boyle et al., Antitrust Law at the Federal Circuit: Red Light or
Green Light at the IP-Antitrust Intersection?, 69 ANTITRUST L.J. 739, 753 (2001) (“[A]
patent owner may properly exercise monopoly power, by charging monopoly prices, in the
markets for those products subject to its patent rights.”); Note, Limiting the Anticompetitive
Prerogative of Patent Owners: Predatory Standards in Patent Licensing, 92 YALE L.J. 831,
831 (1983).
4
See, e.g., R. Locke Bell, Intellectual Property in an Emerging Commercial Spaceflight
Market: Taking Advantage of Other Transaction Authority to Keep Pace with Changing
Commercial Practices, 43 PUB. CONT. L.J. 715, 720 (2014) (“After obtaining a patent,
owners can then license the rights to use or sell their invention for royalties or some other
consideration.”); Bruce Greenhaus, Patentability of Compounds Which Are Structurally
Similar; What’s “New”, 3 HOFSTRA PROP. L.J. 211, 214 (1990).
5
See Jordan Paradise, A Profile of Bio-Pharma Consolidation Activity, 25 ANNALS
HEALTH L. 34, 38 (2016).
6
See 35 U.S.C. § 271(a) (“[W]hoever without authority makes, uses, offers to sell, or
sells any patented invention, within the United States or imports into the United States any
patented invention during the term of the patent therefor, infringes the patent.”).
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competition by way of reduced prices and broader availability of the
patented product.7
Because a patent’s expiration triggers these substantial realignments in the market, each additional day a patent is valid can be
worth millions of dollars for the patent owner and delay the moment
the product becomes more affordable for the public. For example,
after the patent covering Prozac expired, the manufacturer’s profits
dropped, on average, $5 million dollars a day for the next six
months.8 In contrast, consumers benefitted from the drug’s generic
substitutes at discounts of 25% to 40%.9 Similar effects were observed for other drugs, with the drug prices falling 7% to 66%.10
Because the stakes are high, fierce litigation sometimes ensues over
even a single additional day of patent validity.11
Typically, a patent expires twenty years after the filing of a patent application,12 but the patent’s life can be extended to compensate for delays in processing the application.13 Once a patent applicant files a complete patent application, an examiner from the
United States Patent and Trademark Office (“Patent Office”) will
review the application materials14 and either grant the application15
or issue a rejection.16 If a rejection is issued, the applicant will

7

See Gregory J. Glover, The Influence of Market Exclusivity on Drug Availability and
Medical Innovations, 9 THE AAPS J. E312, E313 (2007).
8
Glynn S. Lunney, Jr., On the Continuing Misuse of Event Studies: The Example of
Bessen and Meurer, 16 J. INTELL. PROP. L. 35, 45 (2008) (stating that the revenue the
manufacturer derived from Prozac fell, on average, by $5 million dollars a day after the
patent covering the drug expired).
9
Robert F. Leibenluft & Michael Kades, Antitrust Issues for Life Science Companies,
AM. HEALTH L. ASSOC., AHLA-PAPERS P04300616, at *2 (2006) (Westlaw).
10
See Gerard T. Vondeling et al., The Impact of Patent Expiry on Drug Prices: A
Systematic Literature Review, 16 APPLIED HEALTH ECON. & HEALTH POL’Y 653, 657
(2018).
11
See Complaint at 1, ArQule, Inc. v. Kappos, 793 F. Supp. 2d 214 (D.D.C. 2011) (No.
1:10-cv-01904-ESH) (seeking to increase the PTA of a patent covering a cancer treatment
from 1,127 days to 1,128 days).
12
35 U.S.C. § 154(a)(2).
13
Id. § 154(b)(1)(A).
14
Id. § 131; MPEP § 702 (9th ed. Rev. 10-2019, June 2020).
15
MPEP §§ 1301, 1302.03 (9th ed. Rev. 10-2019, June 2020).
16
37 C.F.R. § 1.104(c) (2002); see also 37 C.F.R. § 1.104(a)(2).
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typically respond either by arguing that the examiner is mistaken or
by amending the patent application to resolve the issues raised in the
rejection.17 This back and forth will continue until either the application is granted18 or the applicant abandons her efforts to obtain a
patent.19 Crucially, at every stage of the application process, both
the examiner and the applicant must act by a mandatory deadline. If
either party is late, the additional time it took to respond is added to
that party’s “delay.”20 Once the patent is issued, the applicant’s total
delay is subtracted from the examiner’s total delay to determine the
Patent Term Adjustment (“PTA”), which is the number of days the
patent is valid beyond the default twenty years.21
The examiner’s and the applicant’s delays are calculated by a
computer program administered by the Patent Office.22 The computer program analyzes the dates of the dozens of pieces of correspondence between the examiner and the applicant, and then the
program applies a complex set of rules to determine the delay of
each party.23 It then subtracts the applicant’s delay from the examiner’s delay to determine the PTA.24 Once the application is approved and the applicant pays the required fees, the Patent Office
notifies her of its PTA determination.25 Unless the applicant

17

37 C.F.R. § 1.121 (2002); MPEP § 714 (9th ed. Rev. 10-2019, June 2020).
See MPEP §§ 1301, 1302.03 (9th ed. Rev. 10-2019, June 2020).
19
See 37 C.F.R. § 1.135(a) (1997).
20
35 U.S.C. § 154(b).
21
See id. § 154(b)(2)(C).
22
MPEP § 2734 03 (9th ed. Rev. 10-2019, June 2020) (“The Office makes the patent
term adjustment determination indicated in the patent by a computer program that uses the
information recorded in the Office’s Patent Application Locating and Monitoring (PALM)
system . . . .”).
23
See id. (“The patent term adjustment provisions of 35 U.S.C. 154(b) are complex,
with numerous types of communications exchanged between applicants and the Office
during the patent application process.”).
24
35 U.S.C. § 154(b)(2)(C).
25
Id. § 154(b)(3)(B) (“[T]he Director shall (i) make a determination of the period of any
patent term adjustment under this subsection, and shall transmit a notice of that
determination no later than the date of issuance of the patent . . . .”).
18
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challenges such determination within two months,26 the Patent Office examiner will not review the computer’s calculation.27
But the computer makes mistakes. The rules for PTA computation are complex,28 and the computer software is buggy. When a
mistake results in the award of a smaller PTA, the mistake cannot
be fixed unless the applicant challenges the PTA determination
within the allotted time.29 In that situation, applicants have an incentive to double-check the Patent Office and ensure that their patents
are extended for as long as possible.
The incentives are more complicated when more PTA is
awarded than is warranted. In theory, the applicant owes a duty of
candor to the Patent Office30 and may request that the agency correct
the excessive PTA.31 In practice, such mistakes often go

26

Id. § 154(b)(3)(B)(ii); 37 C.F.R. § 1.705(b) (2020) (“Any request for reconsideration
of the patent term adjustment indicated on the patent must be by way of an application for
patent term adjustment filed no later than two months from the date the patent was
granted.”).
27
Cf. MPEP § 2734 (“The Office makes the patent term adjustment determination
indicated in the patent by a computer . . . except when an applicant requests reconsideration
pursuant to 37 CFR [§] 1.705.”).
28
MPEP § 2734 (highlighting the complexity of 35 U.S.C. § 154(b)’s patent term
adjustment provisions).
29
See 37 C.F.R. § 1.705(b) (2020).
30
37 C.F.R. § 42.11(a) (2021) (“Parties and individuals involved in the proceeding have
a duty of candor and good faith to the Office during the course of a proceeding.”).
31
MPEP § 2733 (“If a registered practitioner receives a patent term adjustment indicated
on the front of the patent that is longer than expected, the practitioner may disclose the
error to the Office in a letter in compliance with the practitioner’s duty of candor and good
faith in practice before the Office.”) (emphasis added); see Treatment of Letters Stating
That the USPTO’s Patent Term Adjustment Determination Is Greater Than What the
Applicant or Patentee Believes Is Appropriate, 75 Fed. Reg. 42079 (July 20, 2010) (“If the
applicant or patentee wants the [Patent Office] to reconsider its patent term adjustment
determination, the applicant or patentee must use the procedures set forth in [§] 37 CFR
1.705 for requesting reconsideration of a patent term adjustment determination, whether
the [Patent Office’s] patent term adjustment determination is greater than or less than the
adjustment that the applicant or patentee believes to be appropriate. A patentee may also
file a terminal disclaimer at any time disclaiming any period considered in excess of the
appropriate patent term adjustment.”).
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uncorrected, whether due to gamesmanship32 or negligence. Unlike
the deflated PTA, the excessive PTA can be challenged years later
in litigation, if detected.33 Similar to Bruce Willis’s character in the
1999 movie, The Sixth Sense, during the excess PTA, the patent appears alive to most casual observers but is, in fact, dead.34
Based on my original empirical research, I identified two computer bugs resulting in excess PTA. Although it is possible, indeed
likely, that there are more than two bugs plaguing Patent Office’s
software,35 I will focus on these two bugs as they are observed in
more than 27,000 patents and can lead to a substantial amount of
unwarranted PTA, sometimes in the range of 60–90 days. Depending on the industry, these bugs can bestow millions in revenue on
the patent owners36 and force consumers to continue purchasing the
patented product at inflated prices.37
The first bug is that the computer sometime fails to detect some
of the applicant’s delayed replies, which leads to a smaller applicant
delay and an excessive PTA.
The second such bug is that the dates of some correspondence
between the applicant and the examiner will appear backdated in the
records used by the software to determine delays. For example, if
the software believes that an applicant’s late reply to a rejection was
received earlier than it was, the computer will fail to detect the applicant’s delay. In turn, this will lead to a lower applicant delay and
a higher, excessive PTA.
After explaining the problem and assessing its significance, I
propose three solutions.38 The first solution to this problem is for
32

See Neel Guha et al., Vulnerabilities in Discovery Tech, 35 HARV. J.L. & TECH. 581,
606 (stating that intentionality is “nearly impossible to discern” when it comes to software
issues).
33
35 U.S.C. § 282(c)(2).
34
Spoiler alert.
35
See, e.g., Idorsia Pharms. Ltd. v. Iancu, 393 F. Supp. 3d 445, 454–56 (E.D. Va. 2019)
(discussing the computer’s failure to account for the scenario in which a filing date falls on
a Saturday).
36
See Lunney, supra note 8.
37
See Vondeling, supra note 10.
38
See infra Section III.
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patent litigators to diligently double-check the computer’s PTA calculations. Although there is no direct evidence, anecdotal accounts
suggest that patent litigators tend to rely on the PTA calculation.39
Patent prosecutors (who assist inventors in obtaining patents) must
undergo a rigorous exam in order to represent clients at the Patent
Office.40 Part of this examination tests candidates on the complicated PTA rules.41 As we shall see, however, the computer’s mistakes often evade even their trained eyes. Patent litigators, in contrast, need not be barred with the Patent Office as they typically42
represent their clients in federal court.43 Consequently, they are less
familiar with the intricacies of the PTA and are even more likely to
take the computer-generated number for granted. An attentive patent
litigator could invoke 35 U.S.C. § 282(c)(2) to challenge the excess
PTA.44 It is telling, however, that since its promulgation almost forty
years ago,45 that subsection has been invoked exactly zero times in
litigation. In addition, practitioners representing entities seeking approval of generic drugs should similarly take note of these bugs as
they may impact the date on which they need to file their application
with the Food & Drug Administration (FDA).46
39

See infra note 154.
Becoming a Patent Practitioner, U.S. PAT. & TRADEMARK OFF. (Dec. 8, 2021, 12:40
PM), https://www.uspto.gov/learning-and-resources/patent-and-trademark-practitioners/
becoming-patent-practitioner [https://perma.cc/ATA5-8AEB].
41
See U.S. PAT. & TRADEMARK OFF., OFFICE OF ENROLLMENT & DISCIPLINE, GENERAL
REQUIREMENTS BULLETIN FOR ADMISSION TO THE EXAMINATION FOR REGISTRATION TO
PRACTICE IN PATENT CASES BEFORE THE UNITED STATES PATENT AND TRADEMARK OFFICE
19
(2021),
https://www.uspto.gov/sites/default/files/documents/OEDGRB.pdf
[https://perma.cc/ZM9B-BJ8L].
42
Patent litigators also represent clients at the Patent Office during Inter Partes Review
proceedings, which require them to either be barred with the agency or be admitted pro
hac vice. 37 C.F.R. § 42.10(c) (2021).
43
See 28 U.S.C. § 1400(b).
44
35 U.S.C. § 282(c)(2) (“Invalidity of the extension of a patent term or any portion
thereof under section 154(b) . . . because of the material failure . . . by the Director to
comply with the requirements of such section shall be a defense in any action involving
the infringement of a patent during the period of the extension of its term and shall be
pleaded . . . .”).
45
Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98417, § 203, 98 Stat. 1603 (amending 35 U.S.C. § 282 to include the defense).
46
21 CFR 314.94(a)(12)(i)(A)(4); see also Paragraph IV Drug Product Applications:
Generic Drug Patent Challenge Notifications, FDA (Apr. 20, 2021),
40
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The second solution is regulatory and can be implemented by
the Patent Office. To leverage the patent prosecutors’ expertise, the
Patent Office should revise its guidance to require prosecutors to file
the requests to correct the excessive PTA when they become aware
of the mistake, as part of their ethical obligations.47 In addition, in
the notice of issuance informing the applicant of the PTA her patent
is entitled to, a warning should be included to remind patent applicants that errors can happen. To encourage such filings, the Patent
Office should also waive the filing fee for requests asking for a
lower PTA.48 If upon inspection by the examiner the request is
granted, that request should also be forwarded to the Patent Office’s
engineering team to adjust the computer code. This crowdsourcing
of the identification of bugs coupled with a comprehensive review
of the computer software will decrease the number of patents
awarded excessive PTA going forward.
The third solution is a statutory one and, thus, requires Congress’s intervention. Currently, the Patent Office must notify the
applicant of the PTA she is entitled to “no later than the date of
issuance of the patent.”49 By requiring that the agency do the work
for the applicant, the statute decreases the need for the applicant
to double-check the PTA calculations. Instead, Congress could
amend that section to force the applicant to request PTA without the
benefit of seeing the agency’s work, just like a taxpayer must do
with his tax refund. The Patent Office examiner could then compare
the requested PTA with the computer’s output, grant the request if
the two match, and manually double-check the computer’s work if
they do not.

https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/paragraph-iv-drugproduct-applications-generic-drug-patent-challenge-notifications.
47
See supra note 30; see also, Dinis Cheian, Exploring Patent Practitioners’ Duty to
Correct Excess Patent Term Adjustment, IP Watchdog (Oct. 20, 2022),
https://ipwatchdog.com/2022/10/20/exploring-patent-practitioners-duty-correct-excesspatent-term-adjustment/id=152232/ [ https://perma.cc/TV65-GVQZ].
48
37 C.F.R. § 1.705(b)(1). Currently, the fee to file a request for reconsideration is
$210.00. 37 C.F.R. § 1.18(e) (2020).
49
35 U.S.C. § 154(b)(3)(B)(i).
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This Article proceeds in three parts. Part I analyzes the significance of the PTA for patent owners and the basic rules of computing
the adjustment. Part II lays out the two bugs discussed above and
provides examples of real patents that were granted excess PTA.
Finally, Part III walks the reader through potential solutions to the
problem.
I. WHY PTA MATTERS AND HOW IT IS CALCULATED
The expiration date of a patent is of paramount importance because it triggers substantial market realignments. In exchange for
disclosing her invention to the public, the inventor acquires the right
to exclude others from practicing such invention.50 Consequently,
members of the public—including competitors—must either wait
for the patent to expire or acquire the license from the patent
owner,51 lest they risk being the target of an infringement lawsuit.52
Although most patents do not generate significant financial returns for their owners, valuable patents can secure a stream of income from, for example, sales of the invention in a quasi-monopolistic market,53 licensing the patent, or lawsuits.54 The exact percent
of patents that are monetized is unknown,55 but estimates place the
number at somewhere between 5% and 13%.56 Out of the monetized
patents, the generated income varies by industry.57 In general, the
50

35 U.S.C. § 154(a)(1).
See Bell, supra note 4, at 720.
52
See 35 U.S.C. § 271.
53
Boyle, supra note 3, at 753.
54
Katherine E. White, Preserving the Patent Process to Incentivize Innovation in Global
Economy, 13 SYRACUSE SCI. & TECH. L. REP. 1, 25 (2006).
55
See Mark A. Lemley, Rational Ignorance at the Patent Office, 95 NW. U. L. REV.
1495, 1507 (2001) (“It is surprising that we don’t have a very good idea of how many
patents are actually licensed for revenue.”).
56
Id. at 1507 n.53 (2001) (“For what it’s worth, while several academics thought the 5%
number [of licensed patents] was too low, some experienced patent prosecutors told [the
author] it was too high.”); Colleen V. Chien, Software Patents as a Currency, Not Tax, on
Innovation, 31 BERKELEY TECH. L.J. 1669, 1687–88 (2016) (reviewing studies with
estimates for sold patents between 4.5% and 13.5%).
57
Ted Hagelin, Valuation of Patent Licenses, 12 TEX. INTELL. PROP. L.J. 423, 424–25,
432 (2004).
51
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value of a patent, even when monetized, is low.58 One estimate provides that an average licensing agreement results in only $13,000 in
revenue, after patent fees are subtracted.59 Part of the reason for low
values is that, depending on the industry, a single product can be
covered by tens of patents. That is the case in the electronics industry for devices such as smartphones.60
However, many pharmaceutical drugs are protected by only one
or just a handful of patents.61 Once these patents expire, generic
drugs flood the market and can plummet revenues by as much as
90%.62 This can lead to huge losses for the patent holder but benefits
the competitors and the consumers. Indeed, after the Prozac patents
expired in August 2001 and generics flooded the market, the manufacturer’s profits for that drug fell by an average of around $142.67
million monthly for the next six months—almost $5 million per
day.63 On the flip side, consumers could start purchasing generics at
discounts of 25% to 40%.64 Generics for other drugs similarly sell
at discounted prices, ranging from 7% to 66%, following the

58

Zach Kyle, Commercializing Tech Research Has Yet to Fulfill Its Promise, MAGIC
VALLEY (June 27, 2015), http://magicvalley.com/news/local/commercializing-techresearch-has-yet-to-fulfill-itspromise/article_4e64c4f8-90d0-57f9-85fc786e88da2a2e.html [https://perma.cc/5YNT-F8NF].
59
Daniel E. Stern, Stalled Patents: Re-Incentivizing Universities to Review Their
Portfolios of Unlicensed Patents to Achieve the Bayh-Dole Act’s Unfunded Mandate, 45
HOFSTRA L. REV. 1017, 1046 (2017).
60
For example, the iPhone is protected by more than 200 patents. Roy Weinstein et al.,
Taming Complex Intellectual Property Compensation Problems, Micronomics 3–5 (2011),
available
at
https://static1.squarespace.com/static/61b53e492ea58d13b806ccb3/t/61bb823395fe3441a
fc2a503/1639678516406/Taming_Complex_IP_Compensation_Problems.pdf.
61
See Dan L. Burk & Mark A. Lemley, Policy Levers in Patent Law, 89 VA. L. REV.
1575, 1590 (2003) (“In some industries, such as chemistry and pharmaceuticals, a single
patent normally covers a single product.”); Lisa Larrimore Ouellette, How Many Patents
Does It Take to Make a Drug? Follow-On Pharmaceutical Patents and University
Licensing, 17 MICH. TELECOMM. & TECH. L. REV. 299, 300 (2010) (“In fact, most smallmolecule drugs are protected by multiple patents. The average was nearly 3.5 patents per
drug in 2005, with over five patents per drug for the best-selling pharmaceuticals; these
numbers have increased over time.”).
62
Lunney, supra note 8, at 45.
63
Id.
64
Leibenluft & Kades, supra note 9.
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expiration of the patent.65 It is, thus, of little surprise that fierce litigation ensues over even a single day of patent life.66 Accordingly,
determining the exact date when the patent expires is crucial to the
right-holder as well as to the public, especially in industries such as
pharmaceuticals.
A. Calculating Patent Delay: In Theory
The first step in obtaining a patent is submitting a complete patent application.67 Once it is submitted, a Patent Office examiner
will review the filing and either grant the application68 or issue a
rejection, known as an office action.69 One reason for a rejection is
that the examiner discovered publicly available documents, known
as prior art, that pre-date the application and discuss the invention.70
In response to a rejection, the applicant will either argue that the
examiner is incorrect or will amend the application to work around
the prior art.71 This tango, known as patent prosecution,72 will continue until the applicant abandons her efforts or the examiner grants
the application, issuing as a patent shortly thereafter.73
Typically, a patent expires twenty years after the patent application is submitted to the Patent Office.74 That is the minimum term.
However, it is important to note that this default rule does not exactly define the life of the patent itself; as the full duration of the
patent’s life depends on how long the Patent Office takes to grant
the application. Suppose Inventor A and Inventor B both submit

65

Vondeling et al., supra note 10, tbl.2.
See Complaint at 1, ArQule, Inc. v. Kappos, 793 F. Supp. 2d 214 (D.D.C. 2011) (No.
1:10-cv-01904-ESH) (seeking to increase the PTA of a patent covering a cancer treatment
from 1,127 days to 1,128 days).
67
35 U.S.C. § 131; MPEP § 702.
68
MPEP §§ 1301, 1302.03.
69
37 C.F.R. § 1.104(a)(2), (c).
70
See 37 C.F.R. § 1.104(a)(1); MPEP § 901.
71
37 C.F.R. § 1.121; MPEP § 714.
72
Prosecution, in this context, means pursuit. Prosecution, MERRIAM-WEBSTER,
https://www.merriam-webster.com/dictionary/prosecution
[https://perma.cc/SXA48UJU].
73
See 37 C.F.R. § 1.135(a); MPEP §§ 1301, 1302.03.
74
35 U.S.C. § 154(a)(2).
66
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their patent applications on January 1, 2020. If granted, both patents
will expire on January 1, 2040 (twenty years after their filing date in
2020). Now assume that Inventor A’s patent issues on January 1,
2022, but Inventor B’s on January 1, 2024. Because a patent owner’s
rights become enforceable only once the patent issues,75 Inventor A
will enjoy her rights for 18 years, while Inventor B will benefit from
his invention for only 16 years.
In practice, however, Inventor B may benefit for longer than 16
years because Congress directed the Patent Office to extend the life
of the patents that experienced significant delays during prosecution. Such extension is known as a Patent Term Adjustment
(“PTA”)76 and can range from zero77 to thousands of days.78 Three
types of delays extend the life of the patent: identified by the Patent
Office as A Delay, B Delay, and C Delay.79 The first type, A Delay,
generally captures delays incurred because the examiner was too
slow to respond to the filing of a complete application or to an
applicant’s response.80 For example, the first office action must
be issued fourteen months after the filing date81 and subsequent
office actions must follow within four months from the applicant’s
response.82 Thus, if the first office action was issued fifteen months
after the filing date, the life of the patent will be extended by
one month beyond the twenty years. By comparison, B Delay generally accrues if the patent was issued more than three years after
filing.83 Finally, C Delay accumulates during special proceedings,
such as appeals.84

75

But see id. § 154(d) (providing for a narrow exception for the owner to enforce her
rights before issuance of the patent).
76
Id. § 154(b)(1).
77
See, e.g., U.S. Patent No. 6,609,413 (granting 0 days of PTA).
78
See, e.g., U.S. Patent No. 7,053,669 (granting 1,289 days of PTA).
79
35 U.S.C. § 154(b)(1)(A), (B), and (C), respectively; see also 37 C.F.R. § 1.703(a),
(b), and (c), respectively.
80
35 U.S.C. § 154(b)(1)(A); 37 C.F.R. § 1.703(a).
81
35 U.S.C. § 154(b)(1)(A)(i); 37 C.F.R. § 1.703(a)(1).
82
35 U.S.C. § 154(b)(1)(A)(ii); 37 C.F.R. § 1.703(a)(2).
83
35 U.S.C. § 154(b)(1)(B); 37 C.F.R. § 1.703(b).
84
35 U.S.C. § 154(b)(1)(C); 37 C.F.R. § 1.703(c).
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It is important to note that the statutory scheme mandates that
overlapping delays will not be double counted.85 Thus, for example,
an office action that is mailed five months after a response filed three
years into the pendency of the application generates both one month
of A Delay and five months of B Delay. However, the applicant will
only be awarded five months—not six—of PTA because the A Delay overlaps with the B Delay for one month. Furthermore, the sum
of the non-overlapping delays will be diminished by the delays
caused by the applicant.86 Generally, applicants must respond to an
office action within three months.87 However, if for example, the
applicant receives a two-month extension and responds at the fivemonth mark, those two months will be deducted from the PTA.

Perhaps walking through another example will prove helpful. As
illustrated in the figure above, the following events occurred during
the prosecution of our hypothetical patent application: (1) the application is filed on January 1, 2020, (2) the examiner issues an office
action on February 1, 2023, (3) the applicant responds on June 1,
2023, and (4) the patent issues on July 1, 2023.
The PTA calculation is as follows:
=
+
+
)
−(
+

85

See 35 U.S.C. § 154(b)(2); 37 C.F.R. § 1.703(f).
35 U.S.C. § 154(b)(2)(C); 37 C.F.R. § 1.704(a).
87
See 35 U.S.C. § 154(b)(2)(C)(ii); 37 C.F.R. § 1.704(b). However, for a fee, the
applicant can take up to six months to respond without the Patent Office deeming the
application abandoned. MPEP § 7.98.01.
86
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Since there is no C Delay in this case, the formula becomes:
=
+
)
−( &
+
Recall that A Delay accumulates when the Patent Office responds too late to an event.88 In this case, it had fourteen months89
from the moment the application was filed on January 1, 2020 (or
until March 1, 2021), to either grant the application or issue an office
action. It failed to do so, as the office action was issued on February
1, 2023—twenty-three months or 702 days late. This number is our
A Delay. Next, B Delay is the time the Patent Office took to issue
the patent in addition to the three years (expiring on January 1,
2023). In this case, the patent was issued on July 1, 2023, which is
six months or 181 days after the three-year mark.
However, A Delay and B Delay overlap for one month from January 1, 2023 to February 1, 2023. To avoid double counting the delays, such overlap is subtracted from the PTA.90 In this case, the
overlap is 31 days. Finally, the applicant herself was responsible for
some of the B Delay. She had three months to timely respond to the
office action of February 1, 2023.91 She failed to do so and instead
responded on June 1, 2023. Because the applicant cannot be rewarded for her own delays, the 31 days between May 1 and June 1
must be subtracted from the PTA. Thus, the final PTA calculation is
as follows:
) = 821
702
+ 181
− (31
+ 31
The patent will, therefore, expire twenty years and 821 days after
its filing on January 1, 2020, which is April 1, 2042. In the issue
notification, the applicant will be informed of the PTA she is
awarded92 and will have two months to challenge the PTA

88
89
90
91
92

35 U.S.C. § 154(b)(1)(A); 37 C.F.R. § 1.703(a).
See 35 U.S.C. § 154(b)(1)(A)(i); 37 C.F.R. § 1.703(a)(1).
35 U.S.C. § 154(b)(2); 37 C.F.R. § 1.703(f).
See 35 U.S.C. § 154(b)(2)(C)(ii); 37 C.F.R. § 1.704(b).
35 U.S.C. § 154(b)(3)(B).
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calculation.93 The PTA will then be printed on the face of the patent
to notify the public of the expiration date.94
B. Calculating Patent Delay: In Practice
To keep up with the high number of patents issued each day and
the complexities of the calculations, the Patent Office uses a computer program to calculate the PTA.95 The example above is a drastic
simplification of the many possible events, and of the complex PTA
rules triggered by such events, that an application typically undergoes. Because the Patent Office, by statute, must inform the applicant of the PTA she is entitled to, it uses a computer program to
tackle the workload.96 The program uses the information in the Patent Office’s Patent Application Locating and Monitoring
(“PALM”) system—not originally intended to assist in PTA computation—which logs and categorizes different events occurring
during the review of the application.97 For example, in the illustration above, the PALM system would record that the application was
filed on January 1, 2020, that the office action was issued on February 1, 2023, that the response was filed on June 1, 2023, and that the
patent was issued on July 1, 2023. Much like we did in the example
above, the computer program would then apply a set of rules to determine the PTA.98
The Patent Office makes publicly available the information the
computer uses to derive the PTA.99 All that happens during the pendency of the patent application can be seen on the Patent Center
website.100 The page for each application has many tabs but the Patent Term Adjustment tab is of particular importance here. Each
93

Id. § 154(b)(3)(B)(ii); 37 C.F.R. § 1.705(b).
See, e.g., U.S. Patent No. 8,067,555 (“Subject to any disclaimer, the term of this patent
is extended or adjusted under 35 U.S.C. 154(b) by 701 days.”).
95
See MPEP § 2734.
96
Id.
97
See id. (“The PALM system was not originally designed for the purpose of calculating
patent term adjustment as provided in 35 U.S.C. 154(b).”).
98
See id.
99
Patent Center, U.S. PAT. & TRADEMARK OFF., https://patentcenter.uspto.gov
[https://perma.cc/X3ZP-TTP4] (last visited Sep. 22, 2022).
100
See id.
94
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event during prosecution generates one or more entries in that tab.
Along with the sequential number (“Number”) and a description of
the event (“Contents Description”), the event has an associated date
(“Date”), a Patent Office delay field (“PTO (Days)”), an applicant
delay field (“APPL (Days)”), and the number of the event that starts
the delay clock (“Start”).101

101

See, e.g., Patent Center, 13/480,160|BBI005CIP: Powered Lower Extremity Orthotic
and Method of Operation, U.S. PAT. & TRADEMARK OFF., https://patentcenter.
uspto.gov/applications/13480160/patentTermAdjustment [perma.cc/3EF2-ZSZQ] (last
visited Sept. 17, 2022).
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As an example, let us consider the PTA tab for application number 13/480,160.102 The application was filed on May 24, 2012, and
the filing event was assigned sequential number 0.5.103 On June 6,
2012, the examiner notified the applicant that the application was
incomplete due to a missing oath and asked him to pay a surcharge
102
103

Id.
See id (viewing 10 per page hereinafter; select tab 8 at the bottom of the page).
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for filing the oath late (#6, Notice to File Missing Parts of Nonprovisional Application).104 The applicant filed the oath (#13)105 and
paid the fee (#14)106 on February 14, 2013—161 days after the threemonth deadline on September 6, 2012.107 That delay was noted in
the “APPL (Days)” column. The “Start” column helpfully informs
the public of the event that started the clock, in this case event #6,
the notification on June 6, 2012.108
In turn, the examiner was late to issue the first rejection on September 24, 2014 (#45).109 He did so 427 days past the fourteenmonth deadline after the filing (#0.5).110 Finally, the examiner was
late again, this time by 98 days, to issue the notice of allowance
(#73), informing the applicant that the application will issue once
the issuance fee is paid.111 The event starting the examiner’s clock
was the applicant’s response to an office action (labeled as a “nonfinal action”) on June 26, 2015 (#62).112 The examiner had four
months to respond with either a notice of allowance or another office
action. The application then issued as a patent on May 31, 2016
(#83).113 Event #83.5 “PTA 36 months” is an artificial event used to
calculate B Delay from the filing date (#0.5).114 In this case it is 373

104

See id (select tab 7 at the bottom of the page).
See id (select tab 6 at the bottom of the page).
106 See id.
107 See MPEP § 2732 (“The three-month period in 37 CFR 1.704(b) applies to the Office
notices and letters issued as part of the pre-examination processing of an application
(except a Notice of Omitted Items in a Nonprovisional Application as discussed above).
These notices include: (1) a Notice of Incomplete Nonprovisional Application . . . .”).
108 See Patent Center, 13/480,160, supra note 101 (select tab 6 at the bottom of the page).
109
See id. (select tab 3 at the bottom of the page).
110 See id. (select tab 1 at the bottom of the page).
111 See id. (select tab 2 at the bottom of the page).
112 See id.
113 See id. (select tab 1 at the bottom of the page).
114
See id.
105
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days or just a little over a year from the 36-month deadline on May
24, 2015.115

At the top of the PTA tab, a summary of all information relevant
to the calculation of PTA is provided. This tab includes, the total of
A Delays, B Delays, C Delays, the overlap of the delays, the nonoverlapping delays, manual adjustments, applicant delays, and, finally, the awarded PTA.116 In the figure below you can see that the
Patent Office A Delay was 525 days (427 days (#45) + 98 days
(#73)), B Delay was 373 days, and there was no C Delay.117 The
overlap between the A and B Delay was 98 days because the delay
incurred due to the late notice of allowance (#73)118 occurred entirely after the three-year mark on May 24, 2015. The non-overlapping Patent Office delay was, thus, 800 days (525 days + 373 days
– 98 days).119 The applicant delay was 161 days (#14).120 In total,
the PTA adjustment summed up to 639 days (800 days – 161
days).121 Note that the PTO manual adjustment was 0; this field remains 0 unless the Patent Office examiner, following a request for
reconsideration, manually reviews the computer’s calculations and
determines that an adjustment was warranted.122

115

See id.
See id.
117
See id.
118
See id. (select tab 2 at the bottom of the page).
119 Id. (under the “Patent Term Adjustment” summary banner).
120
Id. (select tab 6 at the bottom of the page).
121 Id. (under the “Patent Term Adjustment” summary banner).
122 Id.; see also Explanation of Patent Term Adjustment Calculation, U.S. P
AT. &
TRADEMARK OFF. (Apr. 24, 2014, 2:25 PM), https://www.uspto.gov/patents/
apply/checking-application-status/pair-announcements/explanation-patent-term
[perma.cc/DLF7-RYJX].
116
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Now that we have discussed the basic PTA rules and how the
Patent Office’s computer software applies such rules to the dates
stored in the PALM system, we can discuss the bugs in the system.
II. THE TWO BUGS
Although there are several types of errors, this Part focuses on
two bugs—each identified by me in thousands of granted patents—
that may inflate the PTA term by months. Given that each day of
patent validity can earn the patent owner millions of dollars,123 these
errors are substantial. Although the Patent Office acknowledges that
the software is not perfect due to the complexity of the PTA rules,124
the two issues discussed in this part appear to be coding issues and
not a failure to properly apply an obscure rule to a corner case. The
first bug appears to be an error in the computer program computing
the PTA based on the PALM data, the second an issue with the
PALM data itself.
A. The First Bug: Forgiven Delays
The first bug in the PTA calculation software is that sometimes
the computer fails to penalize applicants for late replies.

123
124

See Lunney, supra note 8.
See MPEP § 2734.
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Consider Application Number 12/835,086 awarded 557 days in
PTA.125 On December 12, 2012, the examiner issued a rejection
(#69), giving the applicant three months to respond.126 The applicant
did not respond within the allotted time; instead, she filed her response on June 6, 2013 (#75), along with a request for extension of
time (#74).127 This tardiness should have resulted in an applicant
delay of 86 days.128 But no such delay was logged by the computer
program, as indicated by the “0” in the “APPL (Days)” column.129

Instead, the only delays that were accounted for in the 96 days
in the “Applicant Delays” field were a late notice of appeal (#91,

125

Patent Center, 12/835,086, Patent Term Adjustment History,
U.S. PAT. & TRADEMARK OFF., https://patentcenter.uspto.gov/applications/12835086/
patentTermAdjustment [perma.cc/M2AC-CECN].
126 Id. (select tab 7 at the bottom of the page).
127 Id.
128 See 35 U.S.C. § 154(b)(2)(C)(ii); 37 C.F.R. § 1.704(b).
129 Patent Center, 12/835,086, supra note 125 (under the “Patent Term Adjustment”
summary banner).
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triggered by #87)130 and a late communication (#123, triggered by
#118).131 Thus, the PTA is inflated by 86 days.
My comprehensive review of all the issued patents as of 2019
uncovered almost 25,000 instances in which an extension resulted
in no delay. To promote empirical research of the process of obtaining a patent, the Patent Office makes available complete datasets for
each patent ever granted, including the logs of the PTA events.132
Using the 2019 dataset, I ran a code that first selected only the patents that had a PTA greater than zero. This step helped ensure that
the undetected applicant delay could impact the final extension; the
PTA cannot be negative. I also eliminated the patents that had a nonzero PTO manual adjustments field since a nonzero adjustment
means that the examiner manually reviewed the computer’s calculations, and likely caught the mistake.133 Then the code scanned each
of the selected patents’ PTA logs and identified the instances in
which the applicant requested an extension but the total applicant

130

Id. (select tab 5 at the bottom of the page).
Id. (select tab 2 at the bottom of the page).
132
See generally Stuart Graham et al., The USPTO Patent Examination Research
Dataset: A Window on the Process of Patent Examination (U.S. PAT. & TRADEMARK OFF.,
Econ. Working Paper No. 2015-4, 2015), https://ssrn.com/abstract=2702637
[https://perma.cc/PV4T-4BGQ]; Patent Examination Research Dataset (PatEx), U.S. PAT.
& TRADEMARK OFF. (Sep. 8, 2022, 2:18 PM), https://www.uspto.gov/ip-policy/economicresearch/research-datasets/patent-examination-research-dataset-public-pair
[perma.cc/XM58-2QZV].
133 Patent Center, 13/480,160, supra note 101 (under the “Patent Term Adjustment”
summary banner).
131
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delay was zero. 24,914 such patents were identified.134 Out of those,
121 have been litigated135 as of 2016.136
B. The Second Bug: Backdated Events
The second bug is that some events appear backdated in the
PALM system, preventing the computer from detecting and
properly computing applicant delays.

134

See, e.g., Patent Center, 13/357,856, Patent Term Adjustment,
U.S. PAT. & TRADEMARK OFF.,
https://patentcenter.uspto.gov/applications/
13357856/patentTermAdjustment [perma.cc/84ZB-XS7T] (select tabs 3 and 4 at the
bottom of the page) (events #27–33 should have caused an applicant delay of 78 days);
Patent Center, 10/980,097, Patent Term Adjustment, U.S. PAT. & TRADEMARK OFF.,
https://patentcenter.uspto.gov/applications/10980097/patentTermAdjustment
[perma.cc/VM47-NZSY] (select tab 3 at the bottom of the page) (events #34 and #36
should have caused applicant delay of 61 days).
135 See, e.g., Patent Center, 13/325,754, Report on the Filing or Determination of an
Action Regarding a Patent or Trademark, (Jan. 5, 2015 and Apr. 7, 2015), U.S. PAT. &
TRADEMARK
OFF.,
https://patentcenter.uspto.gov/applications/13325754/ifw/docs
[perma.cc/ND7L-UGRD]. During prosecution of Application No. 13/325,754, the
applicant requested an extension on May 21, 2014, (#49) to respond to a rejection (#43)
mailed on December 30, 2013, but the delay was never accounted for by the software.
Patent Center, 13/325,754, Patent Term Adjustment, U.S. PAT. & TRADEMARK OFF.,
https://patentcenter.uspto.gov/applications/13325754/patentTermAdjustment
[perma.cc/B7TZ-PJYF].
136 Patent Litigation Docket Reports Data, U.S. P
AT. & TRADEMARK OFF. (Mar. 16, 2022,
5:48 PM), https://www.uspto.gov/ip-policy/economic-research/research-datasets/patentlitigation-docket-reports-data [perma.cc/4TFH-42QW].
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Take for example, application number 15/179,897, issued as a
patent on October 29, 2019 and awarded 115 days of PTA.137 The
examiner mailed a rejection on September 7, 2018 (#43).138 As discussed above and as explained in the office action, the applicant had
three months to respond—until December 7, 2018.139 The applicant
was late, and did not file a response amending the application, until
February 6, 2019 (#50).140 Correctly realizing that his response was
past the three-month deadline, he filed a request for extension of
time (#47).141 This late response should have resulted in 61 days of
delay.142 However, the date of the request appears backdated in the
system: instead of February 6, 2019, it is February 6, 2018, likely
tricking the software into thinking that the response was filed before
the three-month mark.143
We can verify that the request for extension was indeed filed in
2019 in other tabs, such as the “Documents & transaction history”
tab that records events independently from the PALM system.144
Both the dates in that tab and the date in the filed extension request
document itself are February 6, 2019.145

137

Patent Center, 15/179,897, Patent Term Adjustment, U.S. PAT. & TRADEMARK OFF.,
https://patentcenter.uspto.gov/applications/15179897/patentTermAdjustment
[https://perma.cc/MV33-U9GQ].
138
Id. (select tab 5 at the bottom of the page).
139
See 35 U.S.C. § 154(b)(2)(C)(ii); 37 C.F.R. § 1.704(b).
140
Patent Center, 15/179,897, supra note 137 (select tab 4 at the bottom of the page).
141 Id. (select tab 5 from the bottom of the page).
142
Id.
143 Id.
144 Patent Center, 15/179,897, Documents & transaction history, U.S. P
AT. &
TRADEMARK
OFF.,
https://patentcenter.uspto.gov/applications/15179897/ifw/docs
[https://perma.cc/P9PS-ABPQ].
145
Id.

26

FORDHAM INTELL. PROP. MEDIA & ENT. L.J.

[Vol. XXXIII:1

We can also verify that the 61 days in delay were unaccounted
for by reviewing the top panel of the PTA tab.146 The only applicant
delay that was registered is an 87-day delay incurred when the applicant filed a late disclosure statement (triggered by #69).147 The
result in this particular case is that the PTA is inflated by 61 days.
I uncovered more than 2,600 instances in which the applicant’s
reply was backdated. Using the same dataset as for the first bug,148
I first selected the patents with a PTA greater than zero and a zero
PTO manual adjustment and then all the patents in which a reply to
an office action was backdated. This process yielded 2,618 patents.149 Out of those, 21 have been litigated150 as of 2016.151

146

Patent Center, 15/179,897, supra note 137.
Id. (select tab 3 from the bottom of the page).
148 Patent Litigation Docket Reports Data, supra note 136.
149
See, e.g., Patent Center, 15/407,332, Patent Term Adjustment,
U.S.
PAT.
&
TRADEMARK
OFF.,
https://patentcenter.uspto.gov/
applications/15407332/patentTermAdjustment [https://perma.cc/84XT-3NGC] (select tab
3 from the bottom of the page) (events #51 and #53 are backdated, unaccounted delay is
54 days); Patent Center, 15/189,865, Patent Term Adjustment, U.S. PAT. & TRADEMARK
OFF.,
https://patentcenter.uspto.gov/applications/15189865/patentTermAdjustment
[https://perma.cc/3R37-ULB2] (select tabs 3 and 4 at the bottom of the page) (events #49
and #50 are backdated, unaccounted delay is 31 days).
150 See,
e.g., Patent Center, 10/151,220, U.S. PAT. & TRADEMARK OFF.,
https://patentcenter.uspto.gov/applications/10151220
[https://perma.cc/Q4FZ-LMA4]
(events #11 and #12 are backdated, unaccounted delay is 61 days); see also Mike Seymour,
Panavision Sues Canon and Others, FX GUIDE (Jan. 12, 2010),
https://www.fxguide.com/quicktakes/panavision-sues-canon-and-other/
[https://perma.cc/987Z-UPL8].
151
Explanation of Patent Term Adjustment Calculation, supra note 122.
147
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Although the thousands of patents identified above represent
only a small percent of the millions of issued patents152 and although
it is possible that some patents whose PTA is not excessive were
included, the two bugs are certainly not the only ones. Take for example application No. 08/631,331, in which the computer software
erred by a stunning 1,571 days,153 mostly due to improperly classifying a filing as an office action and incorrectly determining the
event that started the delay clock.154 Thankfully, the applicant
caught the mistake and requested the downward adjustment of the
PTA.155
The PTA computation software, therefore, is far from perfect.
And although the Patent Office cautions practitioners that some errors are to be expected due to the complexity of PTA rules,156 the
bugs discussed in this Part involve the simplest of such rules—that
the applicant has three months to respond to an office action before
incurring delays. 157
III. THREE SOLUTIONS
Having identified the problem and assessed its significance, I
now propose three potential solutions for minimizing the effects of
the excess PTA and for improving the Patent Office’s software.

152

PTMT Products and Services Brochure, U.S. PAT. & TRADEMARK OFF.,
https://www.uspto.gov/web/offices/ac/ido/oeip/taf/brochure.htm#:~:text=private%20sect
or%20organizations.,Patents%20and%20Patent%20Activity,granted%20on%20July%2031%2C%201790
[https://perma.cc/UF3Q-2Y93] (“Over 7.8 million United States patents, including over
7.2 million utility patents (‘patents for inventions’) have issued since the first was granted
on July 31, 1790.”).
153
Patent Center, 08/631,331, Patent Term Adjustment, U.S. PAT. & TRADEMARK OFF.,
https://patentcenter.uspto.gov/applications/08631331/patentTermAdjustment
[https://perma.cc/X3YQ-VW46].
154 Patent Center, 08/631,331, Documents & transaction history, Letter Regarding
Patent Term Adjustment (Aug. 24, 2006), U.S. PAT. & TRADEMARK OFF.,
https://patentcenter.uspto.gov/applications/08631331/ifw/docs
[https://perma.cc/C783WCY2].
155 Id. at Request for Review of Patent Adjustment Determination (June 30, 2006).
156 See generally MPEP § 2734.
157
35 U.S.C. § 154(b)(2)(C)(ii); 37 C.F.R. § 1.704(b).
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A. The Private Solution
The first solution is for patent practitioners—especially litigators—to routinely double-check the PTA. Patent prosecutors, who
represent patent applicants at the Patent Office, must be barred with
the agency.158 Although one does not need a law degree to be barred,
aspiring patent prosecutors do need to pass a rigorous, six-hour patent bar exam, colloquially referred to as the “patent bar.”159 Such
exam covers the PTA rules.160 Nevertheless, as we have seen, PTA
mistakes often evade the watchful eye of the patent prosecutor.161 If
the PTA goes uncorrected in the two months allotted for the request
for reconsideration,162 it is unlikely to ever be fixed because unlike
patent prosecutors, patent litigators and transactional patent attorneys are often not admitted with the Patent Office.163 These actors
are less likely to venture into the records of the patent history and to
spot the inflated PTA.164
If the error is detected during patent litigation, defendants are
not without options. “Invalidity of the extension of a patent term . . .
because of the material failure . . . by the Director [of the Patent Office] to comply with the requirements of [the patent statutes] shall
be a defense in any action involving the infringement of a patent
during the period of the extension of its term.”165 Thus, defendants
in patent infringement lawsuits can raise the erroneously granted
PTA as a defense to avoid paying damages during the excess period.
158

See Becoming a Patent Practitioner, supra note 40.
See U.S. PAT. & TRADEMARK OFF., supra note 41 at 19 (“A total of six hours is
permitted for completion of the examination.”).
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161 Note that although “the patentee or the appointed registered practitioner may disclose
the alleged error to the Office in a letter in compliance with the practitioner’s duty of candor
and good faith,” the Patent Office does not require such a filing. MPEP § 2733. But see,
Cheian, supra note 47.
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See 35 U.S.C. § 154(b)(3)(B)(ii); see also 37 C.F.R. § 1.705(b).
163 See David L. Schwartz, The Rise of Contingent Fee Representation in Patent
Litigation, 64 ALA. L. REV. 335, 351–52, 354 (2012).
164 For example, U.S. Patent No. 8,789,986 (which matured from App. No. 13/325,754)
was litigated twice, but the parties did not note that the PTA was excessive, as is evident
from the absence of such allegations in the lawsuits or the Patent Office’s record. See
Patent Center, 13/325,754, supra note 135.
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35 U.S.C. § 282(c)(2).
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Notably absent, however, is a single case in which such a defense
was raised in the almost forty years since that subsection was enacted.166 This lacuna can be interpreted to support the suspicion that
patent litigators rarely check the logs to verify the PTA. Other explanations could be that the defense is raised in confidential communications between the parties or that plaintiffs do not assert patents with excessive PTA are feasible.
Another group of patent practitioners that urgently need to take
heed of these bugs are those assisting pharmaceutical companies
in registering generic drugs with the FDA.167 At the expiration of
a patent covering a drug, entities that would like to sell generic version of the drug need to register the generic with the FDA.168 The
entity that files first for such a registration “has the exclusive right
to market the generic drug for 180 days . . . .”169 As part of the filing,
the entity must certify that the patent covering the original drug
is invalid.170 Thus, lawyers on the lookout for PTA errors may
discover that certain patents expire, and are thus invalid, earlier than
it appears if one blindly relies on the Patent Office’s calculations.
This realization would allow the lawyers to file the generic registration earlier, thus securing the exclusive marketing right for their
clients.171
B. The Regulatory Solution
A second solution is a regulatory fix. First, the Patent Office
should perform an audit of the PTA computing software, identify
issues, and patch them. Realistically, however, the Patent Office will
not be able to detect all the errors because PTA rules are complex
and software bugs can be hard to uncover. The solution would be to
166

Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98417, § 203, 98 Stat. 1585, 1603 (amending 35 U.S.C. § 282 to include the defense).
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21 C.F.R. § 314.94(a)(12)(i)(A)(4).
168 Id.
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Paragraph IV Drug Product Applications: Generic Drug Patent Challenge
Notifications, U.S. FOOD & DRUG ADMIN. (Apr. 20, 2021), https://www.fda.gov/
drugs/abbreviated-new-drug-application-anda/paragraph-iv-drug-product-applicationsgeneric-drug-patent-challenge-notifications [https://perma.cc/R5WX-VJG7].
170 Id.
171
Id.

30

FORDHAM INTELL. PROP. MEDIA & ENT. L.J.

[Vol. XXXIII:1

crowdsource this issue by closely reviewing the requests for reconsideration filed by patent applicants. Every granted request that results in a decreased PTA, and perhaps select request that result in an
increased PTA, should be forwarded to the software team for further
review.
To speed-up the patching of bugs, the Patent Office should mandate that, as part of the prosecutors’ duty of candor, they submit requests to decrease the PTA when they become aware of the mistake.
Prosecutors, and everyone associated with the filing and prosecution
of the application, owe the Patent Office a duty of candor.172 Failure
to adhere to this duty can lead to sanctions173 and to the invalidation
of the patent.174 Currently, however, a failure to file a request to correct excessive PTA is not a violation of the duty.175 The Patent Office should modify that rule to require the filing of the request whenever the prosecutor becomes aware of the mistake.176 In addition, it
should add a statement in the notice of issuance (which includes the
Patent Office’s PTA calculation) reminding patent practitioners of
their new duty. This change would allow the Patent Office to leverage the prosecutors’ expertise and time to fix the software.
Finally, the agency should enact a regulation formally waiving
the fee for filing a request for reconsideration in cases when the request asks for a smaller PTA.177 Although it appears that the current
Patent Office practice is to not assess (in some cases, to) fees for
172

37 C.F.R. § 42.11(a).
37 C.F.R. § 42.11(d)(1).
174 See, e.g., Belcher Pharms., LLC v. Hospira, Inc., 11 F.4th 1345, 1346–48 (Fed. Cir.
2021); see also Mark A. Lemley & Erich Remiker,
Recent Developments in Patent Law 2022 36 (SSRN) (June 8, 2022),
https://ssrn.com/abstract=4131632 [https://perma.cc/FU9A-4T9M].
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MPEP § 2733 (“Note that the Office does not require patentee to file either a request
for reconsideration under 37 CFR 1.705(b) or a terminal disclaimer when the patent term
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appropriate.”); see Treatment of Letters, supra note 31.
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Cf. Boehringer Ingelheim Int’l GmbH v. Barr Lab’ys, Inc., 592 F.3d 1340, 1348 (Fed.
Cir. 2010) (noting that during the excess period of validity “a patentee enjoys an unjustified
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1.705(b)(1), 1.18(e).
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requests to lower the PTA178 (or in some cases, to refund the fees
altogether),179 amending the fee regulation to make this policy clear,
might incentivize prosecutors to file more such requests.
C. The Statutory Solution
The third solution is statutory. If increased vigilance from the
bar and regulatory fixes fail, Congress should amend the statutory
scheme to make patent applicants request PTA without the Patent
Office first sharing its calculations. Currently, 35 U.S.C. § 154 states
that the agency “Director shall . . . make a determination of the period of any patent term adjustment . . . and shall transmit a notice of
that determination no later than the date of issuance of the patent.”180
Therefore, the examiner is statutorily required to provide the PTA
calculation to the patent applicant.181 Congress could amend the statute to instead make applicants petition for PTA, akin to how taxpayers petition the IRS for their tax refunds.182 If no petition is filed, the
PTA shall be set to zero. The patent examiner would then review the
filing and compare the requested PTA with the calculations of the
computer program. If the two match, it is likely that both are correct
since it is hard to imagine the prosecutor and the computer both mistakenly arriving at the same number.
If the two do not match, the examiner should review the PTA
logs and determine if the mistake is the computer’s or the patent
prosecutor’s. If the former is at fault, the examiner would log a request to the software team to investigate the issue. If the latter, the
examiner would grant the request if the prosecutor underestimated
the PTA. However, the examiner would have to provide his PTA
calculation if the prosecutor overestimated the PTA. As is the case
178

See, e.g., Patent Center, 08/631,331, supra note 154.
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35 U.S.C. § 154(b)(3)(B)(i).
181 Alternatively, the Patent Office can take the position that adopting a uniform practice
of informing all patent applicants that they are entitled to zero days of PTA would satisfy
the statute. This interpretation does not strike me as reasonable and is its analysis is beyond
the scope of this paper.
182 See Robert J. Kovacev & Robert C. Morris, Obtaining IRS Refunds: Procedures and
Strategies, TAX EXEC. (Mar. 9, 2022), https://taxexecutive.org/obtaining-irs-refundsprocedures-and-strategies/ [https://perma.cc/QYF9-ERNA].
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currently, the prosecutor would then have a chance, for a fee, to
challenge the examiner’s PTA.
This solution, however, should be of last resort because it will
increase the costs of administering the patent system. Currently, the
examiner manually calculates the PTA only if the applicant files a
petition for reconsideration and pays a fee.183 It is unlikely that Congress will impose a fee on the applicants requesting the PTA they
are owed. Thus, the examiner’s supplemental work will need to be
funded from other sources.
In sum, the issue of inflated PTA can and should be addressed
by first increasing awareness of the problem among the patent bar
and changing the relevant regulations. If these solutions fail, Congress should amend the statute to force applicants to request, as opposed to being provided, the PTA they are entitled to.
Finally, although this is the first Article that discusses bugs in
the Patent Office’s software, the issue of administrative agencies using imperfect computer code is far from unique to the patent system.
Several Articles have analyzed the implication of agencies using
faulty software from a legitimacy standpoint184 and from a constitutional due process view.185 Ultimately, my hope is that this article
will prompt more researchers to critically examine government software not only in the patent context but beyond.
CONCLUSION
The Patent Office’s PTA computer software is buggy. These
bugs result in later expiration of patents and, as discussed previously, in some industries such as pharmaceuticals, a delay in competition that hugely benefits consumers. Although such bugs likely
plague only a small percent of patents, the patent bar should be on
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See 37 C.F.R. § 1.705(b) (2020).
See, e.g., Ryan Calo & Danielle Keats Citron, The Automated Administrative State: A
Crisis of Legitimacy, 70 EMORY L.J. 797, 843 (2021).
185 See, e.g., Margot E. Kaminski & Jennifer M. Urban, The Right to Contest AI, 121
COLUM. L. REV. 1957, 1966 (2021); Danielle Keats Citron, Technological Due Process, 85
WASH. U. L. REV. 1249, 1257 (2008).
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the look-out for these issues and avoid blindly relying on the Patent
Office’s computer. In turn, the Patent Office should order a rigorous
review of its software. If the issue is not successfully resolved, Congress should amend the current statutory regime to require applicants to petition for PTA without the benefit of Patent Office’s calculations.

